1,018 results on '"Baldini, C"'
Search Results
2. Adequate assessment yields appropriate care—the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group
3. Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients
4. Patients’ selection and trial matching in early-phase oncology clinical trials
5. Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
6. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study
7. POS1238 LACRIMAL GLAND ULTRA-HIGH FREQUENCY ULTRASOUND IN SJÖGREN’S DISEASE: DIAGNOSTIC ACCURACY AND CLINIC-SEROLOGICAL ASSOCIATIONS OF DISTINCT SONOGRAPHIC PATTERNS
8. AB0793 THE USE OF NATURAL LANGUAGE PROCESSING TO CHARACTERIZE DISEASE BURDEN: SEXUAL DISTRESS IN SJÖGREN’S DISEASE
9. POS0348 PHENOTYPIC STRATIFICATION AND LONG-TERM OUTCOME OF PRIMARY SJÖGREN’S SYNDROME-RELATED INTERSTITIAL LUNG DISEASE
10. POS1265 ULTRA HIGH-FREQUENCY ULTRASOUND (UHFUS) OF LABIAL GLANDS IN PRIMARY SJÖGREN’S SYNDROME: ASSOCIATIONS AMONG SONOGRAPHIC PATTERNS, HISTOLOGY AND AUTOANTIBODIES SPECIFICITIES AND TITER
11. POS1247 CHARACTERIZATION OF 284 PATIENTS PRESENTING WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OF SJÖGREN DISEASE: RESULTS FROM THE SJÖGREN BIG DATA REGISTRY
12. POS1242 PREDICTORS AND PATTERN OF DAMAGE AT 15-YEAR FOLLOW-UP IN AN ITALIAN MULTI-CENTER PRIMARY SJÖGREN’S SYNDROME COHORT: A HIERARCHICAL CLUSTERING ANALYSIS
13. POS1249 FACTORS ASSOCIATED WITH PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN SJÖGREN’S DISEASE: A REAL LIFE SINGLE-CENTRE STUD
14. AB0834 ANTICENTROMERE ANTIBODIES IN THE SETTING OF SJÖGREN SYNDROME: ANALYSIS OF A MULTICENTRIC COHORT
15. POS1246 CHARACTERIZATION OF 785 PATIENTS WITH PULMONARY MANIFESTATIONS OF SJÖGREN DISEASE: RESULTS FROM THE BIG DATA SJÖGREN REGISTRY
16. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
17. Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort
18. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group
19. Cancer Diagnosis
20. Amplifying voices in Sjögrens and Lupus communities through social listening: real-world evidence from their sleep experiences
21. 6O Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials
22. Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review
23. Bridging the gap: addressing disparities of access to oncology clinical trials in the geriatric population
24. Safety and efficacy of antibody drug conjugates in older patients with solid tumors
25. Clonal Hematopoiesis of indeterminate potential in patients with advanced NSCLC treated with ICB
26. Tolerance and efficacy of immunotherapy: a worth trade-off for non-frail older patients with cancer
27. P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study
28. ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART
29. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study
30. Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
31. Cancer Diagnosis
32. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
33. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
34. AB0601 THE MENTAL HEALTH IMPACT OF SEXUAL DYSFUNCTION IN SJÖGREN’S DISEASE: A SOCIAL MEDIA APPROACH TO REAL-WORLD EVIDENCE
35. AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE
36. LB0003 Dazodalibep (VIB4920/HZN4920) in Sjögren’s Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind Study
37. POS1461 ADVANTAGES OF DOPPLER IN LABIAL SALIVARY GLAND ULTRA-HIGH FREQUENCY ULTRASOUND: CORRELATIONS WITH HISTOLOGICAL INFLAMMATION, pSS DIAGNOSIS, DISEASE ACTIVITY, AND PROGNOSIS
38. POS1459 THE WEIGHT OF ANTI-LA/SSB ANTIBODIES IN RO/SSA-POSITIVE PATIENTS WITH A NEWLY DIAGNOSED SJÖGREN’S SYNDROME: A PHENOTYPE CHARACTERIZED BY A MORE SEVERE MAJOR AND MINOR GLANDULAR INVOLVEMENT AND A HIGHER BIOLOGICAL ACTIVITY
39. AB0804 THE PERFORMANCE OF ACR 1990 AND ACR/EULAR 2022 CRITERIA IN THE DIAGNOSIS OF GPA AND EGPA
40. AB0491 COMPARATIVE STUDY ON THE SHORT-TERM EFFICACY AND OUTCOME OF JANUS KINASE INHIBITORS: A SINGLE-CENTER RETROSPECTIVE OBSERVATIONAL STUDY
41. POS1453 PROGRESSIVE PULMONARY FIBROSIS ACCORDING TO THE NEW ATS DEFINITION IS NOT UNCOMMON IN THE CONTEXT OF SJÖGREN’S SYNDROME-ASSOCIATED INTERSTITIAL LUNG DISEASE
42. POS1463 FACTORS ASSOCIATED WITH DISEASE DAMAGE AT 20 YEAR FOLLOW-UP IN AN ITALIAN MULTICENTER SJÖGREN’S SYNDROME COHORT
43. Systemic vasculitis: one year in review 2023
44. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis
45. Systemic vasculitis: one year in review 2022
46. 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
47. 85P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
48. 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
49. 2P Outcomes of patients with gynecological tumors harboring HER2 defects: A single center study based on Gustave Roussy cancer center’s molecular program
50. Utilisation de la double immunothérapie par anti-CTLA-4 et anti-PD-1 chez les patients octogénaires et nonagénaires atteints de mélanome en France : premières données de l’étude rétrospective multicentrique IpiNivOver80
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.